Cambridge Investment Research Advisors, Inc. Heron Therapeutics, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $27.1 Billion
- Q2 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 14,867 shares of HRTX stock, worth $26,760. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,867
Previous 10,867
36.81%
Holding current value
$26,760
Previous $30,000
73.33%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding HRTX
# of Institutions
198Shares Held
129MCall Options Held
94.7KPut Options Held
148K-
Rubric Capital Management LP New York, NY26.7MShares$48.1 Million2.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.62MShares$15.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$15 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.6MShares$13.7 Million0.05% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$12.6 Million58.47% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $214M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...